Evolution of Nanoparticle Protein Corona across the Blood-Brain Barrier.
暂无分享,去创建一个
Fulvio Magni | Alessandro Corbelli | Fabio Fiordaliso | Silke Krol | Clizia Chinello | Alysia Cox | Francesco Stellacci | Massimo Masserini | Francesca Re | M. Masserini | S. Krol | F. Stellacci | F. Fiordaliso | F. Re | F. Magni | C. Chinello | A. Corbelli | A. Cox | P. Andreozzi | R. Dal Magro | L. Talamini | F. Raimondo | M. Tringali | Paulo H Jacob Silva | Laura Talamini | Francesca Raimondo | Patrizia Andreozzi | Roberta Dal Magro | Maria Tringali | Paulo Jacob Silva | Francesca Raimondo
[1] Shabir Hassan,et al. Biophysicochemical perspective of nanoparticle compatibility: a critically ignored parameter in nanomedicine. , 2014, Journal of nanoscience and nanotechnology.
[2] Peiyu Pu,et al. SURFACE MULTI-FUNCTIONALIZATION OF POLY(LACTIC ACID) NANOPARTICLES AND C6 GLIOMA CELL TARGETING in vivo , 2009 .
[3] M. Cipolla. The Cerebral Circulation , 2016 .
[4] Korsmeyer Richard Wilker. Critical questions in development of targeted nanoparticle therapeutics , 2016 .
[5] M. Wolfert,et al. Controlled Multi-functionalization Facilitates Targeted Delivery of Nanoparticles to Cancer Cells. , 2016, Chemistry.
[6] S. Mitragotri,et al. Nanoparticles in the clinic , 2016, Bioengineering & translational medicine.
[7] B. Dahlbäck,et al. The nanoparticle protein corona formed in human blood or human blood fractions , 2017, PloS one.
[8] W. Pardridge,et al. Drug Transport across the Blood–Brain Barrier , 2012, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[9] M. Kanoh,et al. Serum Matrix Metalloproteinase-2 Levels Indicate Blood–CSF Barrier Damage in Patients with Infectious Meningitis , 2008, Inflammation.
[10] Krunal K. Mehta,et al. Biomineralized anisotropic gold microplate-macrophage interactions reveal frustrated phagocytosis-like phenomenon: a novel paclitaxel drug delivery vehicle. , 2014, ACS applied materials & interfaces.
[11] Mojca Pavlin,et al. Dispersion of Nanoparticles in Different Media Importantly Determines the Composition of Their Protein Corona , 2017, PloS one.
[12] F. Stellacci,et al. A centrifugation-based physicochemical characterization method for the interaction between proteins and nanoparticles , 2016, Nature Communications.
[13] Nathalie Y. R. Agar,et al. Blood-brain-barrier spheroids as an in vitro screening platform for brain-penetrating agents , 2017, Nature Communications.
[14] Nicholas A Peppas,et al. A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics. , 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[15] V. Muzykantov,et al. Multifunctional Nanoparticles: Cost Versus Benefit of Adding Targeting and Imaging Capabilities , 2012, Science.
[16] G. Sancini,et al. The hunt for brain Aβ oligomers by peripherally circulating multi-functional nanoparticles: Potential therapeutic approach for Alzheimer disease. , 2016, Nanomedicine : nanotechnology, biology, and medicine.
[17] L. Campbell,et al. Evaluation of the immortalised mouse brain capillary endothelial cell line, b.End3, as an in vitro blood–brain barrier model for drug uptake and transport studies , 2003, Brain Research.
[18] R. Upadhyay. Drug Delivery Systems, CNS Protection, and the Blood Brain Barrier , 2014, BioMed research international.
[19] M. Masserini,et al. Liposomes functionalized to overcome the blood–brain barrier and to target amyloid-β peptide: the chemical design affects the permeability across an in vitro model , 2013, International journal of nanomedicine.
[20] F. Stellacci,et al. Lipid tail protrusions mediate the insertion of nanoparticles into model cell membranes , 2014, Nature Communications.
[21] E. Tasciotti,et al. Mesoporous silica nanoparticles trigger mitophagy in endothelial cells and perturb neuronal network activity in a size- and time-dependent manner , 2017, International journal of nanomedicine.
[22] Beom-Jin Lee,et al. Protein corona: a new approach for nanomedicine design , 2017, International journal of nanomedicine.
[23] Ajay-Vikram Singh,et al. Nanoparticle enabled drug delivery across the blood brain barrier: in vivo and in vitro models, opportunities and challenges. , 2014, Current pharmaceutical biotechnology.
[24] Omid C Farokhzad,et al. Insight into nanoparticle cellular uptake and intracellular targeting. , 2014, Journal of controlled release : official journal of the Controlled Release Society.
[25] Samuel T. Jones,et al. Broad-spectrum non-toxic antiviral nanoparticles with a virucidal inhibition mechanism. , 2018 .
[26] M. Masserini,et al. Novel Antitransferrin Receptor Antibodies Improve the Blood-Brain Barrier Crossing Efficacy of Immunoliposomes. , 2016, Journal of pharmaceutical sciences.
[27] G. Morelli,et al. Receptor binding peptides for target-selective delivery of nanoparticles encapsulated drugs , 2014, International journal of nanomedicine.
[28] Lode Vereeck,et al. Future of nanomedicine: obstacles and remedies. , 2011, Nanomedicine.
[29] F F SAVERIO,et al. [Cerebral circulation]. , 1954, Omnia therapeutica. Supplemento.
[30] P. Gaillard,et al. Relationship between permeability status of the blood-brain barrier and in vitro permeability coefficient of a drug. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[31] Francesco Stellacci,et al. Surface-structure-regulated cell-membrane penetration by monolayer-protected nanoparticles. , 2008, Nature materials.
[32] Á. Kittel,et al. A new blood–brain barrier model using primary rat brain endothelial cells, pericytes and astrocytes , 2009, Neurochemistry International.
[33] P. Couraud,et al. The hCMEC/D3 cell line as a model of the human blood brain barrier , 2013, Fluids and Barriers of the CNS.
[34] P. Kantoff,et al. Cancer nanomedicine: progress, challenges and opportunities , 2016, Nature Reviews Cancer.
[35] Stefan Tenzer,et al. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. , 2013, Nature nanotechnology.
[36] M. Sitti,et al. Microemulsion-Based Soft Bacteria-Driven Microswimmers for Active Cargo Delivery. , 2017, ACS nano.
[37] Erno Pungor,et al. Proteomic Analysis for the Assessment of Different Lots of Fetal Bovine Serum as a Raw Material for Cell Culture. Part IV. Application of Proteomics to the Manufacture of Biological Drugs , 2008, Biotechnology progress.
[38] Mauro Ferrari,et al. Seven challenges for nanomedicine. , 2008, Nature nanotechnology.
[39] L. Fenart,et al. In vitro model for evaluating drug transport across the blood-brain barrier. , 1999, Advanced drug delivery reviews.
[40] Y. Kariya,et al. Evaluation of blood-brain barrier function by quotient alpha2 macroglobulin and its relationship with interleukin-6 and complement component 3 levels in neuropsychiatric systemic lupus erythematosus , 2017, PloS one.
[41] Fabio Fiordaliso,et al. Multifunctional Liposomes Reduce Brain β-Amyloid Burden and Ameliorate Memory Impairment in Alzheimer's Disease Mouse Models , 2014, The Journal of Neuroscience.
[42] K. Dawson,et al. The Intracellular Destiny of the Protein Corona: A Study on its Cellular Internalization and Evolution. , 2016, ACS nano.
[43] F. Magni,et al. Intraluminal proteome and peptidome of human urinary extracellular vesicles , 2015, Proteomics. Clinical applications.
[44] M. Masserini,et al. The ability of liposomes, tailored for blood-brain barrier targeting, to reach the brain is dramatically affected by the disease state. , 2018, Nanomedicine.
[45] A. Aires,et al. Multifunctionalization of magnetic nanoparticles for controlled drug release: a general approach. , 2014, European journal of medicinal chemistry.
[46] Jong-Min Lim,et al. Mechanistic understanding of in vivo protein corona formation on polymeric nanoparticles and impact on pharmacokinetics , 2017, Nature Communications.
[47] V. Torchilin,et al. Current trends in the use of liposomes for tumor targeting. , 2013, Nanomedicine.